Has Alan Shah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $64 in general payments to Alan Shah, MD across 3 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alan Shah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alan Shah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alan Shah, MD

Cardiovascular Disease · New York, NYNPI 1922105642

Payments from drug & device makers

$64in general payments, 2019–2025

Across 3 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amarin Pharma, Inc.$40
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$24

What the payments were for

Food & beverage$64100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amarin Pharma, Inc.	2	$40
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$24

How this compares

$64 in reported general payments places this provider in the 5th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York →

Medicare billing

Part B allowed, 2024

$650,270

Medicare patients

1,099

Services billed

10,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	595	$829,042
Repatha SureclickEvolocumab	207	$158,309
XareltoRivaroxaban	86	$134,826
EntrestoSacubitril/Valsartan	99	$122,123
JardianceEmpagliflozin	78	$102,063
MultaqDronedarone Hcl	28	$56,418
Praluent PenAlirocumab	46	$32,994
VascepaIcosapent Ethyl	42	$31,187
BrilintaTicagrelor	32	$28,616
Rosuvastatin Calcium	1,091	$21,593
Ezetimibe	619	$21,434
LivaloPitavastatin Calcium	17	$16,228
Metoprolol Succinate	820	$14,707
Repatha SyringeEvolocumab	23	$12,258
Atorvastatin Calcium	929	$11,202

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New York

James MinNew York$41.1M
Robert RosensonNew York$6.9M
Roxana MehranNew York$6.4M
Roger HajjarNew York$5.2M
Philippe GenereuxNew York$4.4M
Gregg StoneNew York$3.7M
Valentin FusterNew York$2.9M
Tamim NazifNew York$2.2M
Howard WeintraubNew York$1.7M
Anuradha Lala-TrindadeNew York$1.5M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →